Introduction
The association between obesity and cardiovascular risk has been described in multiple epidemiological studies, and is now universally accepted [1] . However, this is far from a straightforward relationship; for any given body mass index (BMI), there is significant variability, with some lean individuals developing disease and others remaining healthy despite severe obesity, the so-called metabolically healthy obese [2] . A significant part of this variability can be attributed to variation in fat distribution and depot differences in adipose tissue function.
Adipose tissue is unique in that it is dispersed throughout the body in discreet depots, which are thought to constitute "separate mini organs" [3] . Almost 90 % of the adipose tissue is found subcutaneously (subcutaneous adipose tissue-SAT), mainly in the abdominal, gluteal and femoral areas. Visceral adipose tissue (VAT) and smaller depots close to the heart (epicardial adipose tissue-EAT), kidneys, joints, eyes, etc., make up the remaining 10-20 % [4] . The size of each depot and the balance between them is important for the cardiometabolic risk of the individual: a peripheral fat distribution (in the limbs) is favorable and a central one (truncal, both subcutaneous and visceral) is detrimental, as will be discussed in more detail later. The mechanisms linking fat distribution and cardiovascular risk are complex and involve changes in whole-body glucose concentrations and lipid metabolism, effects on traditional and novel cardiovascular risk factors (e.g., hypertension, inflammation), and the systemic or local actions of adipokines secreted by the adipose tissue.
Epidemiological and Imaging Studies Link Adipose Tissue Depots and Atherosclerosis Risk, Severity, and Progression

Central Obesity and Cardiovascular Morbidity and Mortality
The idea that central fat distribution is associated with higher disease risk is far from novel [5] and is supported by a wealth of epidemiological and clinical data (reviewed in [6] ). In a meta-analysis of 58 prospective studies of more than 220,000 individuals free of cardiovascular disease, the hazard ratio Peripheral Fat Accumulation is Protective Recent systematic reviews identified and summarized data on 37,725 individuals followed up on average for 11.2 years in nine prospective cohort studies that examined the relationship between hip circumference and cardiovascular disease risk (three studies), cardiovascular mortality (four), or total mortality (two studies) [13•, 14] . All but one reported an inverse association between hip circumference and the respective outcome in both male and female subjects. This association became apparent only after adjustment for waist circumference and/or BMI. Owing to the strong bivariate associations between BMI and waist and hip circumference, as they all reflect total adiposity, it is important to make adjustments for BMI and waist circumference in any model to reveal the independent effects of hip circumference on cardiovascular morbidity and mortality [13•, 14] . In addition, peripheral fat distribution is associated with traditional risk factors, lower blood pressure, improved insulin sensitivity, and a beneficial lipid profile, as reviewed before [15] .
Peripheral fat distribution is also an integral part of the metabolically healthy obese phenotype [16] [17] [18] . The incidence of cardiovascular disease among these individuals is in some studies comparable to the incidence in the normal-weight population [17] [18] [19] [20] [21] , and in other studies is intermediate between the incidence in normal-weight and metabolically unhealthy obese subjects [22] , but altogether is significantly lower than what would be expected solely on the basis of BMI.
Anthropometric Indices for Clinical Predictions
The question that arises from the epidemiological studies briefly discussed so far is whether measurements of fat distribution should become a standard part of the everyday assessment of cardiovascular risk. This question was formally addressed in the Emerging Risk Factors Collaboration study, which showed that addition of BMI, waist circumference, waist-to-hip ratio, or of their combination does not improve cardiovascular risk prediction over and above that based on systolic blood pressure, history of diabetes, and lipids [7] . Nevertheless, the American Heart Association in its most recent scientific statement on the assessment of adiposity recommends measurement of both BMI and waist circumference in everyday clinical practice. It also emphasizes the need for sex-, age-, race-and BMI-specific cutoff values of waist circumference [23••] . In a population study, the optimal BMI and waist circumference thresholds for the identification of increased cardiovascular risk appear to be comparable in white and African American men ( [24] . However, when VAT area was assessed by computed tomography, the threshold for increased cardiovascular risk was higher in both white men and white women compared with African American men and women (140 cm 2 versus 82 cm 2 in men, 141 cm 2 versus 97 cm 2 in women) [25] . In addition, a number of new indices have been proposed as superior to the use of BMI or circumference measurements (summarized in Table 1 ).
Insights from Imaging Studies
From a different point of view, it can be argued that anthropometric indices are only indirect measures and possibly poor approximations of the respective adipose tissue depots. Waist circumference reflects VAT as well as abdominal SAT, whereas hip circumference depends on the amount of gluteal fat, but also on muscle mass. With the advent of detailed imaging techniques, it is possible to obtain more accurate measurements of the above-mentioned depots, together with smaller, so far overlooked, depots.
Computed tomography and magnetic resonance imaging (MRI) studies can examine the independent associations of abdominal SAT and VAT with risk factors and disease. Both earlier and more recent studies indicate that VAT [40] [41] [42] and the ratio between VAT and SAT [43] show the closest correlations with cardiometabolic risk. In addition, increased VAT for comparable BMI appears to mediate the adverse metabolic profile of South Asian and East Asian populations [44, 45] .
Epicardial and Perivascular Adipose Tissues in Relation to Atherosclerosis
Given their anatomical proximity to the heart, the coronary arteries, or other arteries susceptible to atherosclerosis, the EAT, pericardial adipose tissue, and perivascular adipose tissue depots have attracted considerable interest over the last few years. In cross-sectional studies, higher amounts of EAT/ pericardial adipose tissue are associated with higher prevalence of cardiovascular disease; this relationship is seen in both sexes and is attenuated after adjustment for BMI and other risk factors [46] [47] [48] . Interestingly, increased pericardial and periaortic depots do not always coexist, and significant discordance is noted in more than 20 % of individuals [49] . The thoracic periaortic adipose tissue is more closely associated with central obesity and metabolic syndrome, but its associations with cardiovascular risk or disease are less significant and become apparent only after adjustment for VAT [48] [49] [50] .
More recently, prospective data have started accumulating: the volume of EAT [51] and its expansion [52] were both associated with an increase of coronary artery calcification over time. In patients with established coronary artery disease (n =194, age 59.4 years, 80 % men, BMI 28.7±4.6 kg/m 2 ), EAT measured by echocardiography was not predictive of new major cardiovascular events over a follow-up period of 3.6 years [53] . In the general population though, EAT is predictive of future coronary events: among 4,093 participants in the Heinz Nixdorf Recall cohort study (age 59.4 years, 47 % men, follow-up 8.0 years), doubling of the amount of EAT was associated with a 1. Trefethen [39] "New BMI"
No data available BMI Body mass index, h height, HC hip circumference, HDL high-density lipoprotein, TG triglycerides, w weight, WC waist circumference artery and vein. Increased renal sinus fat, also called "fatty kidney," was associated with the presence of hypertension in two middle-aged populations, and this relationship remained significant after accounting for BMI and/or VAT [55, 56] . The breast adipose tissue has been studied in MRI studies of healthy, premenopausal women with a wide range of adiposity, and its volume correlated positively with central obesity and VAT, and negatively with leg adipose tissue. No associations were found with cardiovascular risk factors in either of these studies [57, 58] .
Pathophysiological Mechanisms That Link Specific Depots to Cardiometabolic Disease
Elucidating the mechanisms that differentiate the significance of each depot is a challenging scientific question that is potentially important for disease prevention and treatment.
Factors such as the cellular characteristics, the location, and the function of different adipose tissue deposits have all been linked to their effects in three major hypotheses, as discussed in the following sections (see also Fig. 1 ).
The Subcutaneous Sink and the Toxicity of Ectopic Adipose Tissue
The subcutaneous depots are often considered as the main adipose sites that ensure effective energy deposition under conditions of caloric excess and release under conditions of negative energy balance. According to this hypothesis, accumulation of fat as VAT and in the smaller internal depots reflects the inability of SAT to store further triglycerides and has detrimental effects on the surrounding tissues, particularly liver, skeletal muscle, and the heart [59] . This is evident in the case of lipodystrophies [60] and in the use of thiazolidinediones (rosiglitazone or pioglitazone): administration of pioglitazone to overweight/obese, insulin-resistant but nondiabetic subjects induced adipogenesis and expansion of the volume of SAT and reduction of the volume of VAT and improved insulin sensitivity [61] .
Adipokines and Endocrine Effects
By synthesizing and releasing a number of cytokines and other proteins, adipose tissue exerts endocrine effects on a number of tissues, the vasculature itself and others that contribute indirectly to cardiovascular disease, such as the liver and skeletal muscle. Adipokines, such as leptin, interleukin-6, interleukin-8, monocyte chemoattractant protein 1, serum amyloid A, plasminogen activator inhibitor 1, angiotensinogen, and an array of others, are upregulated in obesity and can affect all stages of atherosclerosis from monocyte recruitment to foam cell formation, smooth muscle cell proliferation, plaque destabilization, and thrombosis (reviewed in [62, 63] ). Although a detailed description of their individual effects is outside of the scope of this review, specific mention is required of adiponectin, a highly abundant circulating hormone. In contrast to other adipokines, whose levels are increased in obesity, adiponectin levels are reduced in obese individuals. In addition to BMI, adiponectin levels are influenced by sex (higher levels in women than in men), ethnicity (higher levels in Caucasians than in Hispanics and African Americans), and fat distribution (positively correlated with lower body fat and negatively correlated with truncal fat) [64] . Circulating adiponectin levels are associated with cardiovascular disease, but in a complex way: in the general population, adiponectin is inversely related to traditional risk factors and future events; in older individuals, this association is U-shaped with a protective effect for concentrations up to 12.4 mg/L [65] . In contrast, in populations with preexisting cardiovascular disease, higher adiponectin levels are associated with poorer prognosis [65] [66] [67] . In agreement with epidemiological data, recent in vitro studies suggest that under certain experimental conditions, adiponectin can have adverse effects on macrophages and T cells [68] , in addition to its better established atheroprotective effects (reviewed in [69, 70] ). Thus, the exact role of adiponectin in chronic inflammatory states remains poorly understood [71] .
The Portal Hypothesis and Other Local/Direct Effects of Smaller Depots
The portal hypothesis posits that, when enlarged, the lipolytically active VAT releases significant amounts of free fatty acids directly to the portal circulation and consequently to the liver [72] . These in turn will be transported to the systemic circulation in very low density lipoproteins, will stimulate hepatic glucose production, and will suppress hepatic insulin clearance, leading to dyslipidemia, hyperinsulinemia, and insulin resistance [72] . Indeed, it was shown that with visceral obesity the contribution of VAT to the free fatty acids that reach the liver increases from less than 10 % to more than 30-40 % [73] . However, increased concentration of free fatty acids in the portal circulation compared with the systemic circulation has not been documented in humans (reviewed in [74] ) and most of the free fatty acids that reach the liver are derived from SAT, and particularly the upper-body SAT, even in obese individuals [73] . In addition to free fatty acids, VAT releases interleukin-6 to the portal vein, which in turn induces synthesis of C-reactive protein in the liver and contributes to systemic inflammation [75] .
Smaller adipose tissue depots, such as the epicardial one, are probably devoid of systemic effects. On the other hand, they may have pathophysiological significance because of their effects on the heart and the coronary arteries. In in vitro studies, adipokines produced by EAT can induce expression of adhesion molecules in human coronary artery endothelial cells and migration of monocytes [76] and affect the contractile function and insulin responses of cardiomyocytes [77] , as well as fibrosis of the atrial myocardium [78] . Perivascular adipose tissue can regulate vascular tone and thus blood pressure control through the release of a relaxing factor, recently identified as methyl palmitate [79] . Finally, obesity is accompanied by reduced angiogenesis and capillarization within the adipose tissue itself, which may be linked to the concomitant inflammation and insulin resistance [80, 81] .
Experimental Studies to Establish Firmly the Independent Roles of Separate Depots
It has to be noted that although new data are accumulating steadily on the characteristics of each adipose tissue depot and on their relationship to metabolic and cardiovascular diseases, studies that will establish a direct, causal relationship are extremely difficult. They require experimental manipulations that will target a specific depot and alter its function without affecting the rest of the depots or total body adiposity. Very few studies provide such information, but there are some important insights from some clinical studies and animal models, as described in the following sections.
A Mouse Model Without Perivascular Adipose Tissue
Murine perivascular adipose tissue has features of brown adipose tissue and as a result, it can generate heat to preserve intravascular temperature on exposure to cold temperatures [82•] . A mouse model in which the adipogenic transcription factor peroxisome-proliferator-activated receptor γ was deleted specifically in smooth muscle cells was characterized by complete lack of perivascular adipose tissue with normal subcutaneous and gonadal depots. Studies of this model show that activation of perivascular fat by exposure to cold Fig. 1 Adipose tissue depots influence the development of atherosclerosis through multiple direct and indirect mechanisms. Subcutaneous adipose tissue depots (abdominal, gluteal, and femoral) release in the systemic circulation free fatty acids (FFA) and numerous adipokines/cytokines that affect the function of critical tissues (liver, skeletal muscle, kidney, heart, vessel wall) and have detrimental effects on traditional (dyslipidemia, hypertension, diabetes) or novel (inflammation) cardiovascular risk factors.
Visceral adipose tissue products are drained through the portal vein directly to the liver and affect hepatic function, and a proportion of them enter the systemic circulation and have systemic effects. Smaller depots may have local effects: the perivascular fat can interact with the vessel wall, the epicardial fat with the myocardium and the coronary arteries, and the renal sinus fat with the renal artery/vein. AT adipose tissue temperatures can attenuate high-fat-diet induced atherosclerosis, at least partly through enhanced lipid clearance and prostacyclin release [82•] . Although the relevance of these findings for humans is unclear, the study demonstrates the potential of this depot to modulate vascular damage in vivo.
Omental Adipose Tissue in Humans: How Important is it?
As already discussed, the links between VAT and cardiometabolic disease have attracted extensive interest. However, VAT correlates closely with intrahepatic triglyceride content, and it has been proposed that the former represents mostly a marker of the latter, rather than a hazardous tissue per se. Thus, obese, middle-aged individuals with high intrahepatic triglyceride content have reduced insulin sensitivity in comparison with others with equal levels of VAT but low intrahepatic triglyceride content. In contrast, individuals with high VAT were as insulin-sensitive as those with low levels of VAT provided that they were matched for intrahepatic triglyceride content [83] . These findings are in accordance with interventional studies that involve removal of the omental depot in obese individuals. In eight of nine published studies, addition of omentectomy to gastric bypass or sleeve gastrectomy did not augment weight loss or the improvement in insulin sensitivity and other metabolic indices achieved by the bariatric intervention itself (Table 2) [84••, [85] [86] [87] [88] [89] [90] [91] . Although longer-term follow-up and the incidence of cardiovascular events can be assessed in future studies, these data question the causative role of omental adipose tissue in metabolic dysfunction.
Diet, Exercise, and Visceral Adiposity
Identification of dietary patterns associated preferentially with central obesity and high cardiovascular risk can be of major public health significance. In a cross-sectional assessment of diet of 497,308 individuals (age 25-70 years, 70.7 % women) from ten European countries, adherence to a Mediterranean diet, enriched in vegetables, fruits, legumes, and unsaturated fatty acids and low in meat and dairy products, was associated with significantly lower waist circumference in both men and women, but not with BMI [92] . A similar dietary pattern, high in fruits and low in processed meat, margarine, soft drinks, and white bread, was related to smaller increases in waist circumference during 5.5 years of follow-up in the 48,631 participants of the European Prospective Investigation into Cancer and Nutrition [93] . These observational data support the findings of a recent randomized trial: a study comparing two Mediterranean diets, supplemented with olive oil or mixed nuts, with a control, low-fat, diet was terminated prematurely owing to lower incidence of major cardiovascular events in the Mediterranean diet groups Caloric restriction induces weight loss, and women appear to lose more VAT as a percentage of total body fat loss compared with men [95] . However, there is no specific diet that preferentially targets VAT: diets with 25 % versus 15 % protein, 40 % versus 20 % fat, and 65 % versus 35 % carbohydrates all resulted in similar reductions in total body fat, lean mass, abdominal SAT, and VAT [95] .
Exercise is the second feature of a healthy lifestyle. In overweight and obese adults, aerobic exercise alone, without concomitant caloric restriction, can lead to significant reduction of VAT after 12 weeks; in contrast, resistance training has no significant effects on VAT [96, 97] . In addition, some studies report that exercise can facilitate VAT reductions during diet-induced weight loss [98] or prevent VAT regain after successful dieting and weight loss [99] (reviewed in [6] ).
Brown Adipose Tissue in Humans:
It Exists-How Important is it?
The "rediscovery" of brown adipose tissue in adult humans [100] has created a lot of scientific interest in the molecular and physiological properties of this depot. Because of its ability to dissipate energy as heat by uncoupling oxidative phosphorylation and ATP synthesis (a function of uncoupling protein 1), brown adipose tissue is seen as a potential new therapeutic tool to combat obesity. Although outside the scope of this review, there is now evidence that adipocytes that express uncoupling protein 1 are present in humans in small depots with the characteristics of classic brown adipose tissue [101] , but also interspersed in the white adipose tissue depots, so-called brite or beige adipocytes [102] . The amount of brown adipose tissue depends on several factors, including sex, age, and BMI [103] , and is increased after surgical weight loss [104] . In animal models, multiple hormones, molecular pathways, and pharmacological agents (from catecholamines, natriuretic peptides, and the retinoic acid pathway to irisin and thiazolidinediones; reviewed in [105] ) can expand and activate brown/brite-beige fat. Translational studies will be needed to clarify whether these tissues affect whole body metabolism in humans and to identify efficient tools to use them to achieve cardiometabolic health.
Conclusions
Obesity is now recognized as a major public health issue and a driver of a number of comorbidities, including cardiovascular disease. A more recent notion is that obesity is a heterogeneous condition. Body fat distribution, which reflects the size of the larger fat depots, provides an additional level of risk classification for obese individuals and is now a recommended part of everyday clinical practice. Smaller depots, such as the epicardial one, when located in critical areas, may interact directly with important tissues, such as the vessel wall, the myocardium, and the renal vessels, but their in vivo significance remains unknown. Although epidemiological studies have provided and continue to provide ample data, unraveling the effects of each depot in experimental studies remains a big challenge. As a result, therapeutic approaches that will target specific fat deposits are currently lacking, and maintaining a healthy body weight through lifestyle measures is still the cornerstone of cardiometabolic health.
